Barney S. Graham
#17,311
Most Influential Person Now
American immunologist, virologist, and clinical trials physician in viral pathogenesis, immunity, and vaccine development
Barney S. Graham's AcademicInfluence.com Rankings
Barney S. Grahambiology Degrees
Biology
#851
World Rank
#1482
Historical Rank
#458
USA Rank
Virology
#48
World Rank
#50
Historical Rank
#19
USA Rank
Immunology
#75
World Rank
#81
Historical Rank
#26
USA Rank
Download Badge
Biology
Barney S. Graham's Degrees
- PhD Microbiology University of North Carolina at Chapel Hill
Why Is Barney S. Graham Influential?
(Suggest an Edit or Addition)According to Wikipedia, Barney S. Graham is an American immunologist, virologist, and clinical trials physician. He is currently Professor of Medicine and Microbiology, Biochemistry, & Immunology and Senior Advisor for Global Health Equity at Morehouse School of Medicine in Atlanta. He is the former deputy director of the Vaccine Research Center , part of the National Institute of Allergy and Infectious Diseases , National Institutes of Health . During his tenure at the VRC, Graham also served as chief of the Viral Pathogenesis Laboratory.
Barney S. Graham's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation (2020) (6900)
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine (2020) (5634)
- An mRNA Vaccine against SARS-CoV-2 — Preliminary Report (2020) (2366)
- Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 (2021) (1071)
- Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults (2020) (1020)
- Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 (2021) (1004)
- SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness (2020) (846)
- Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen (2017) (837)
- Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates (2020) (809)
- Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine (2013) (693)
- Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus (2013) (687)
- Pre-fusion structure of a human coronavirus spike protein (2016) (630)
- Zika virus protection by a single low dose nucleoside modified mRNA vaccination (2017) (624)
- Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody (2013) (619)
- Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination (2020) (613)
- Rapid COVID-19 vaccine development (2020) (585)
- Animal models for COVID-19 (2020) (582)
- Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. (2013) (536)
- Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. (1991) (518)
- Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19 (2021) (505)
- Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection (2015) (501)
- Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8+ T cell responses (2007) (498)
- Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation (2020) (494)
- Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo (2010) (485)
- Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. (1996) (479)
- Broad neutralization of SARS-related viruses by human monoclonal antibodies (2020) (464)
- Viral and Host Factors in Human Respiratory Syncytial Virus Pathogenesis (2007) (457)
- Proof of principle for epitope-focused vaccine design (2014) (446)
- Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies (2020) (443)
- Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis (2018) (421)
- The histopathology of fatal untreated human respiratory syncytial virus infection (2007) (418)
- mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants (2021) (418)
- Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. (1993) (398)
- Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection (2015) (380)
- Primary respiratory syncytial virus infection in mice (1988) (369)
- Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. (2016) (344)
- Rapid development of a DNA vaccine for Zika virus (2016) (340)
- Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization (2021) (333)
- A Recombinant Vesicular Stomatitis Virus Ebola Vaccine (2017) (333)
- Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody (2016) (329)
- Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. (2006) (328)
- Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants (2021) (322)
- Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants (2021) (322)
- Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing Epitopes (2011) (319)
- Herpesvirus DNA Is Consistently Detected in Lungs of Patients with Idiopathic Pulmonary Fibrosis (2003) (305)
- A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases (2018) (301)
- A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. (2015) (295)
- Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine (2021) (286)
- Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase (2021) (278)
- Protection against malaria at 1 year and immune correlates following PfSPZ vaccination (2016) (277)
- Evaluation of candidate vaccine approaches for MERS-CoV (2015) (275)
- Prefusion F–specific antibodies determine the magnitude of RSV neutralizing activity in human sera (2015) (275)
- The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. (2018) (275)
- The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates (2021) (270)
- Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection against Lentiviral Infection In Vivo (2014) (243)
- Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses (2016) (241)
- Mechanism of Neutralization by the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 (2011) (240)
- A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial (2008) (236)
- Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site (2015) (234)
- A DNA Vaccine for Ebola Virus Is Safe and Immunogenic in a Phase I Clinical Trial (2006) (229)
- Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. (2006) (224)
- Immunological and Virological Analyses of Persons Infected by Human Immunodeficiency Virus Type 1 while Participating in Trials of Recombinant gp120 Subunit Vaccines (1998) (220)
- Biological challenges and technological opportunities for respiratory syncytial virus vaccine development (2011) (215)
- Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV‐1 human monoclonal antibody VRC01 in healthy adults (2015) (214)
- Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial (2014) (213)
- Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials (2017) (210)
- Strategic priorities for respiratory syncytial virus (RSV) vaccine development (2013) (209)
- A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. (2010) (202)
- Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. (1998) (201)
- The Role of IFN in Respiratory Syncytial Virus Pathogenesis (2002) (197)
- Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease. (2013) (194)
- Chimpanzee Adenovirus Vector Ebola Vaccine (2017) (192)
- Priming with Secreted Glycoprotein G of Respiratory Syncytial Virus (RSV) Augments Interleukin-5 Production and Tissue Eosinophilia after RSV Challenge (1998) (190)
- Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial (2016) (190)
- DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials (2011) (189)
- Broadly Neutralizing Activity of Zika Virus-Immune Sera Identifies a Single Viral Serotype. (2016) (188)
- Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection (2017) (188)
- Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule (2009) (186)
- NK T Cells Contribute to Expansion of CD8+ T Cells and Amplification of Antiviral Immune Responses to Respiratory Syncytial Virus (2002) (185)
- Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection (1986) (184)
- Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants (2021) (184)
- Flow Cytometry Reveals that H5N1 Vaccination Elicits Cross-Reactive Stem-Directed Antibodies from Multiple Ig Heavy-Chain Lineages (2014) (181)
- A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. (1999) (180)
- Diversion of HIV-1 vaccine–induced immunity by gp41-microbiota cross-reactive antibodies (2015) (179)
- Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates (2021) (176)
- In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies (2021) (175)
- Maturation of West Nile Virus Modulates Sensitivity to Antibody-Mediated Neutralization (2008) (175)
- A proof of concept for structure-based vaccine design targeting RSV in humans (2019) (170)
- Serum and nasal-wash immunoglobulin G and A antibody response of infants and children to respiratory syncytial virus F and G glycoproteins following primary infection (1986) (166)
- A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. (2007) (166)
- Structural and molecular basis for Ebola virus neutralization by protective human antibodies (2016) (166)
- Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. (2007) (165)
- Transgenic Overexpression of Interleukin (IL)-10 in the Lung Causes Mucus Metaplasia, Tissue Inflammation, and Airway Remodeling via IL-13-dependent and -independent Pathways* (2002) (165)
- Structural basis of respiratory syncytial virus neutralization by motavizumab (2010) (162)
- Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses (2018) (160)
- Secreted Respiratory Syncytial Virus G Glycoprotein Induces Interleukin-5 (IL-5), IL-13, and Eosinophilia by an IL-4-Independent Mechanism (1999) (160)
- Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus. (1994) (155)
- Trypsin Treatment Unlocks Barrier for Zoonotic Bat Coronavirus Infection (2019) (154)
- Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in newborn macaques (2016) (153)
- Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors (2016) (150)
- Augmentation of Human Immunodeficiency Virus Type 1 Neutralizing Antibody by Priming with gp160 Recombinant Vaccinia and Boosting with gp160 in Vaccinia-Naive Adults (1993) (149)
- A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204) (2011) (148)
- The Safety and Immunogenicity of a Human Immunodeficiency Virus Type 1 (HIV-1) Recombinant gp160 Candidate Vaccine in Humans (1991) (148)
- Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses (2010) (147)
- Illness severity, viral shedding, and antibody responses in infants hospitalized with bronchiolitis caused by respiratory syncytial virus. (2002) (146)
- Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults (2018) (145)
- Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape (2018) (142)
- QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. (2001) (141)
- High-Throughput Mapping of B Cell Receptor Sequences to Antigen Specificity (2019) (141)
- Selective cyclooxygenase-1 and -2 inhibitors each increase allergic inflammation and airway hyperresponsiveness in mice. (2002) (139)
- Phenotypic and Functional Profile of HIV-Inhibitory CD8 T Cells Elicited by Natural Infection and Heterologous Prime/Boost Vaccination (2010) (138)
- SARS-CoV-2 Viral Variants-Tackling a Moving Target. (2021) (137)
- Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant (2021) (136)
- Prior Dengue Virus Exposure Shapes T Cell Immunity to Zika Virus in Humans (2017) (136)
- Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. (2016) (133)
- Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants (2021) (133)
- Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network. (1992) (133)
- Opportunistic infections in endogenous Cushing's syndrome. (1984) (132)
- Regulatory T Cells Promote Early Influx of CD8+ T Cells in the Lungs of Respiratory Syncytial Virus-Infected Mice and Diminish Immunodominance Disparities (2009) (132)
- Next-generation influenza vaccines: opportunities and challenges (2020) (131)
- LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants (2021) (130)
- A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. (2011) (129)
- Immune-mediated disease pathogenesis in respiratory syncytial virus infection. (2000) (128)
- SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness (2020) (128)
- LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection (2020) (127)
- Herpes Simplex Virus Infection of the Adult Lower Respiratory Tract (1983) (126)
- Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization (2021) (126)
- Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses. (2012) (125)
- Vaccine development for respiratory syncytial virus. (2017) (124)
- Corrigendum: Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state (2017) (123)
- Respiratory syncytial virus infection in the absence of STAT 1 results in airway dysfunction, airway mucus, and augmented IL-17 levels. (2005) (120)
- Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine - Preliminary Report. (2021) (119)
- Fc Glycan-Mediated Regulation of Placental Antibody Transfer (2019) (119)
- Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. (2013) (119)
- Antiviral Activity of Lovastatin against Respiratory Syncytial Virus In Vivo and In Vitro (2001) (118)
- A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172). (2010) (118)
- Structure-Based Vaccine Antigen Design. (2019) (118)
- Clinical trials of HIV vaccines. (2002) (117)
- A single-dose live-attenuated vaccine prevents Zika virus pregnancy transmission and testis damage (2017) (117)
- Respiratory syncytial virus in allergic lung inflammation increases Muc5ac and gob-5. (2004) (115)
- Phase 2 Study of an HIV-1 Canarypox Vaccine (vCP1452) Alone and in Combination With rgp120: Negative Results Fail to Trigger a Phase 3 Correlates Trial (2007) (115)
- Overexpression of interleukin-4 delays virus clearance in mice infected with respiratory syncytial virus (1997) (115)
- Zika Virus: Immunity and Vaccine Development (2016) (113)
- Neutralizing Antibodies to HIV-1 in Seronegative Volunteers Immunized With Recombinant gp 120 From the MN Strain of HIV-1 (1994) (111)
- Accelerated COVID-19 vaccine development: milestones, lessons, and prospects (2021) (111)
- RhoA Signaling Is Required for Respiratory Syncytial Virus-Induced Syncytium Formation and Filamentous Virion Morphology (2005) (111)
- Respiratory syncytial virus infection prolongs methacholine‐induced airway hyperresponsiveness in ovalbumin‐sensitized mice (1999) (110)
- Safety and Immunogenicity of DNA Vaccines Encoding Ebolavirus and Marburgvirus Wild-Type Glycoproteins in a Phase I Clinical Trial (2014) (107)
- High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. (2009) (107)
- Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus. (2011) (106)
- Structure of a Major Antigenic Site on the Respiratory Syncytial Virus Fusion Glycoprotein in Complex with Neutralizing Antibody 101F (2010) (106)
- History of passive antibody administration for prevention and treatment of infectious diseases (2015) (106)
- Strain-specific serum antibody responses in infants undergoing primary infection with respiratory syncytial virus. (1988) (105)
- Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein (2015) (105)
- Prolonged Production of TNF-α Exacerbates Illness during Respiratory Syncytial Virus Infection1 (2004) (104)
- Candidate AIDS vaccines. (1995) (104)
- Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial (2015) (103)
- Smallpox vaccines: Past, present, and future (2006) (102)
- Pathogenesis of respiratory syncytial virus vaccine-augmented pathology. (1995) (102)
- Quadrivalent influenza nanoparticle vaccines induce broad protection (2021) (101)
- Consensus summary report for CEPI/BC March 12–13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines (2020) (101)
- Serologic cross-reactivity of SARS-CoV-2 with endemic and seasonal Betacoronaviruses (2020) (100)
- Safety and Immunogenicity Study of Multiclade HIV-1 Adenoviral Vector Vaccine Alone or as Boost following a Multiclade HIV-1 DNA Vaccine in Africa (2010) (100)
- Subunit Recombinant Vaccine Protects against Monkeypox1 (2006) (100)
- Pathogenesis of respiratory syncytial virus infection in the murine model. (2005) (97)
- Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that Lack Somatic Hypermutation (2018) (97)
- Mutations in the Spike Protein of Middle East Respiratory Syndrome Coronavirus Transmitted in Korea Increase Resistance to Antibody-Mediated Neutralization (2018) (97)
- Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial (2017) (96)
- Validation of a SARS-CoV-2 spike protein ELISA for use in contact investigations and serosurveillance (2020) (93)
- Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network. (1994) (93)
- Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals. (2007) (92)
- A RhoA-derived peptide inhibits syncytium formation induced by respiratory syncytial virus and parainfluenza virus type 3 (2000) (92)
- Cyclooxygenase inhibition increases interleukin 5 and interleukin 13 production and airway hyperresponsiveness in allergic mice. (2000) (91)
- Respiratory Syncytial Virus (RSV) G Glycoprotein Is Not Necessary for Vaccine-Enhanced Disease Induced by Immunization with Formalin-Inactivated RSV (2004) (91)
- Novel antigens for RSV vaccines. (2015) (91)
- IL-13 Is Sufficient for Respiratory Syncytial Virus G Glycoprotein-Induced Eosinophilia After Respiratory Syncytial Virus Challenge 1 (2003) (91)
- Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic (2017) (91)
- Safety and Immunogenicity of a High‐Titered Canarypox Vaccine in Combination With rgp120 in a Diverse Population of HIV‐1‐Uninfected Adults: AIDS Vaccine Evaluation Group Protocol 022A (2002) (91)
- RhoA Interacts with the Fusion Glycoprotein of Respiratory Syncytial Virus and Facilitates Virus-Induced Syncytium Formation (1999) (91)
- Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus (2016) (91)
- Modified vaccinia Ankara: potential as an alternative smallpox vaccine. (2004) (90)
- Functional Interrogation and Mining of Natively-Paired Human VH:VL Antibody Repertoires (2017) (89)
- Intranasal administration of RSV antigen-expressing MCMV elicits robust tissue-resident effector and effector memory CD8+ T cells in the lung (2016) (89)
- Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group. (1998) (89)
- Activation Dynamics and Immunoglobulin Evolution of Pre-existing and Newly Generated Human Memory B cell Responses to Influenza Hemagglutinin. (2019) (89)
- Structural Analysis of Respiratory Syncytial Virus Reveals the Position of M2-1 between the Matrix Protein and the Ribonucleoprotein Complex (2014) (88)
- Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections (2016) (87)
- Respiratory syncytial virus infection does not increase allergen‐induced type 2 cytokine production, yet increases airway hyperresponsiveness in mice (2001) (85)
- Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV (2016) (85)
- Safety and Immunogenicity of a Candidate HIV-1 Vaccine in Healthy Adults: Recombinant Glycoprotein (rgp) 120: A Randomized, Double-Blind Trial (1996) (84)
- Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials (2017) (83)
- Role of Plasma Membrane Lipid Microdomains in Respiratory Syncytial Virus Filament Formation (2003) (83)
- Tailored design of protein nanoparticle scaffolds for multivalent presentation of viral glycoprotein antigens (2020) (83)
- Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial virus FG subunit vaccine. (1997) (83)
- Safety and Immunogenicity of a Fully Glycosylated Recombinant gp160 Human Immunodeficiency Virus Type 1 Vaccine in Subjects at Low Risk of Infection (1993) (82)
- LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants (2022) (82)
- H5N1 Vaccine–Elicited Memory B Cells Are Genetically Constrained by the IGHV Locus in the Recognition of a Neutralizing Epitope in the Hemagglutinin Stem (2015) (82)
- Respiratory Syncytial Virus Glycoprotein G Interacts with DC-SIGN and L-SIGN To Activate ERK1 and ERK2 (2011) (81)
- Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group. (1997) (81)
- Respiratory syncytial virus immunobiology and pathogenesis. (2002) (80)
- Quantitative and Qualitative Deficits in Neonatal Lung-Migratory Dendritic Cells Impact the Generation of the CD8+ T Cell Response (2014) (80)
- Vaccines against respiratory syncytial virus: The time has finally come. (2016) (79)
- IL-4 Diminishes Perforin-Mediated and Increases Fas Ligand-Mediated Cytotoxicity In Vivo1 (2000) (78)
- Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study (2019) (78)
- Human peripheral blood xenografts in the SCID mouse: characterization of immunologic reconstitution. (1993) (78)
- Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529 (2021) (77)
- Interleukin-4 Diminishes CD8+ Respiratory Syncytial Virus-Specific Cytotoxic T-Lymphocyte Activity In Vivo (1999) (77)
- A live RSV vaccine with engineered thermostability is immunogenic in cotton rats despite high attenuation (2016) (77)
- Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule (2009) (77)
- Immunological Lessons from Respiratory Syncytial Virus Vaccine Development. (2019) (77)
- Challenges and Opportunities for Respiratory Syncytial Virus Vaccines (2013) (76)
- Alternative Mechanisms of Respiratory Syncytial Virus Clearance in Perforin Knockout Mice Lead to Enhanced Disease (2001) (76)
- Cytotoxic T Cell and Neutralizing Antibody Responses to Human Immunodeficiency Virus Type 1 Envelope with a Combination Vaccine Regimen (1998) (75)
- Primary Human mDC1, mDC2, and pDC Dendritic Cells Are Differentially Infected and Activated by Respiratory Syncytial Virus (2011) (75)
- Prevalence of HCV coinfection in HIV-infected individuals in Nigeria and characterization of HCV genotypes. (2004) (74)
- Safety and Immunogenicity of Env 2-3, a Human Immunodeficiency Virus Type 1 Candidate Vaccine, in Combination with a Novel Adjuvant, MTP-PE/MF59 (1996) (73)
- Publisher Correction: Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis (2018) (73)
- Novel Vaccine Technologies: Essential Components of an Adequate Response to Emerging Viral Diseases. (2018) (73)
- Vβ14+ T Cells Mediate the Vaccine-Enhanced Disease Induced by Immunization with Respiratory Syncytial Virus (RSV) G Glycoprotein but Not with Formalin-Inactivated RSV (2004) (72)
- Neonatal CD8 T-cell Hierarchy Is Distinct from Adults and Is Influenced by Intrinsic T cell Properties in Respiratory Syncytial Virus Infected Mice (2011) (71)
- Respiratory syncytial virus infection in anti-mu-treated mice (1991) (71)
- Design of Nanoparticulate Group 2 Influenza Virus Hemagglutinin Stem Antigens That Activate Unmutated Ancestor B Cell Receptors of Broadly Neutralizing Antibody Lineages (2019) (71)
- Preferential induction of cross-group influenza A hemagglutinin stem–specific memory B cells after H7N9 immunization in humans (2017) (70)
- Interleukin-12 treatment during immunization elicits a T helper cell type 1-like immune response in mice challenged with respiratory syncytial virus and improves vaccine immunogenicity. (1995) (70)
- Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies (2020) (69)
- Structural Definition of a Neutralization-Sensitive Epitope on the MERS-CoV S1-NTD (2019) (69)
- Serologic Cross-Reactivity of SARS-CoV-2 with Endemic and Seasonal Betacoronaviruses (2021) (69)
- Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120. (2001) (69)
- T cell source of type 1 cytokines determines illness patterns in respiratory syncytial virus-infected mice. (1997) (68)
- Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network. (1994) (68)
- Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice (2021) (68)
- Advances in antiviral vaccine development (2013) (68)
- Efficacy of an Adjuvanted Middle East Respiratory Syndrome Coronavirus Spike Protein Vaccine in Dromedary Camels and Alpacas (2019) (67)
- Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk. (2019) (66)
- RhoA is activated during respiratory syncytial virus infection. (2001) (66)
- DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after rAd5 Boost in a Randomized Clinical Trial (2013) (65)
- The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates (2021) (65)
- Immune interaction between respiratory syncytial virus infection and allergen sensitization critically depends on timing of challenges. (2001) (64)
- Reinfection of mice with respiratory syncytial virus (1991) (63)
- Differential Specificity and Immunogenicity of Adenovirus Type 5 Neutralizing Antibodies Elicited by Natural Infection or Immunization (2009) (63)
- Prolonged production of TNF-alpha exacerbates illness during respiratory syncytial virus infection. (2004) (62)
- Immunological determinants of disease caused by respiratory syncytial virus. (1996) (62)
- Safety and Immunogenicity of Therapeutic DNA Vaccination in Individuals Treated with Antiretroviral Therapy during Acute/Early HIV-1 Infection (2010) (62)
- Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine–boosted nonhuman primates (2021) (62)
- Suppression of airway hyperresponsiveness induced by ovalbumin sensitisation and RSV infection with Y-27632, a Rho kinase inhibitor (2002) (62)
- V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network. (1993) (61)
- Serum vitamin A levels in respiratory syncytial virus infection. (1994) (61)
- T cell immunity to SARS-CoV-2 following natural infection and vaccination (2020) (60)
- Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate (2015) (59)
- DNA priming prior to inactivated influenza A(H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent manner in adults. (2013) (59)
- A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice (2021) (58)
- Interpreting HIV Serodiagnostic Test Results in the 1990s: Social Risks of HIV Vaccine Studies in Uninfected Volunteers (1994) (58)
- Immunization with Cocktail of HIV-Derived Peptides in Montanide ISA-51 Is Immunogenic, but Causes Sterile Abscesses and Unacceptable Reactogenicity (2010) (58)
- Influenza Virus H5 DNA Vaccination Is Immunogenic by Intramuscular and Intradermal Routes in Humans (2012) (58)
- Safety and Immunogenicity of a Gag-Pol Candidate HIV-1 DNA Vaccine Administered by a Needle-Free Device in HIV-1-Seronegative Subjects (2007) (58)
- Protective Role of TNF-alpha in respiratory syncytial virus infection in vitro and in vivo. (1996) (57)
- Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state (2017) (57)
- TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity. (2009) (57)
- Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial (2017) (57)
- Responses against a Subdominant CD8+ T Cell Epitope Protect against Immunopathology Caused by a Dominant Epitope (2010) (57)
- HIV-DNA Priming Alters T Cell Responses to HIV-Adenovirus Vaccine Even When Responses to DNA Are Undetectable (2011) (56)
- Lymph Node Activation by PET/CT Following Vaccination With Licensed Vaccines for Human Papillomaviruses (2017) (56)
- Germline-Encoded Affinity for Cognate Antigen Enables Vaccine Amplification of a Human Broadly Neutralizing Response against Influenza Virus. (2019) (56)
- Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees. (1993) (56)
- Comparison of adaptive and innate immune responses induced by licensed vaccines for human papillomavirus (2014) (55)
- Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial. (2020) (55)
- Two-Component Ferritin Nanoparticles for Multimerization of Diverse Trimeric Antigens. (2018) (54)
- Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data (2021) (54)
- SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn (2021) (54)
- Lessons from failure--preparing for future HIV-1 vaccine efficacy trials. (2005) (54)
- Challenges and opportunities in RSV vaccine development: Meeting report from FDA/NIH workshop. (2016) (53)
- Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054) (2010) (53)
- Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire. (2013) (52)
- Identification of an H-2Db-restricted CD8+ cytotoxic T lymphocyte epitope in the matrix protein of respiratory syncytial virus (2005) (52)
- Immunoprophylaxis and Immunotherapy of Respiratory Syncytial Virus–Infected Mice with Respiratory Syncytial Virus–Specific Immune Serum (1993) (52)
- Respiratory Syncytial Virus Infection Reinforces Reflex Apnea in Young Lambs (1992) (52)
- The Morphology and Assembly of Respiratory Syncytial Virus Revealed by Cryo-Electron Tomography (2018) (51)
- ETHICAL CONSIDERATIONS FOR ZIKA VIRUS HUMAN CHALLENGE TRIALS (2017) (50)
- Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. (2019) (50)
- Signaling through the Prostaglandin I2 Receptor IP Protects against Respiratory Syncytial Virus-Induced Illness (2004) (48)
- Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein (2017) (48)
- A Platform Incorporating Trimeric Antigens into Self-Assembling Nanoparticles Reveals SARS-CoV-2-Spike Nanoparticles to Elicit Substantially Higher Neutralizing Responses than Spike Alone (2020) (48)
- Immune Correlates of Protection by mRNA-1273 Immunization against SARS-CoV-2 Infection in Nonhuman Primates (2021) (47)
- A Virus-Like Particle Vaccine Elicits Broad Neutralizing Antibody Responses in Humans to All Chikungunya Virus Genotypes. (2016) (47)
- Cyclooxygenase Inhibition Augments Allergic Inflammation through CD4-Dependent, STAT6-Independent Mechanisms1 (2005) (46)
- Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions (2021) (46)
- Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial. (2019) (45)
- Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection (2004) (45)
- Erratum: Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies (Cell (2020) 181(5) (1004–1015.e15), (S0092867420304943), (10.1016/j.cell.2020.04.031)) (2020) (45)
- Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120 (2017) (45)
- Report from the World Health Organization's Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 7–9th Sep 2015☆ (2016) (45)
- Safety and Immunogenicity of an HIV Adenoviral Vector Boost after DNA Plasmid Vaccine Prime by Route of Administration: A Randomized Clinical Trial (2011) (44)
- Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung (2021) (43)
- Determinants of early life immune responses to RSV infection. (2016) (42)
- The quest for a T cell-based immune correlate of protection against HIV: a story of trials and errors (2011) (42)
- A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats (2016) (42)
- Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates (2021) (41)
- A Filovirus-Unique Region of Ebola Virus Nucleoprotein Confers Aberrant Migration and Mediates Its Incorporation into Virions (2008) (41)
- Thermoresponsive Polymer Nanoparticles Co-deliver RSV F Trimers with a TLR-7/8 Adjuvant. (2016) (41)
- Breast Milk Prefusion F Immunoglobulin G as a Correlate of Protection Against Respiratory Syncytial Virus Acute Respiratory Illness (2018) (41)
- Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes (2020) (41)
- Respiratory syncytial virus vaccine research and development: World Health Organization technological roadmap and preferred product characteristics. (2018) (40)
- A Cysteine Zipper Stabilizes a Pre-Fusion F Glycoprotein Vaccine for Respiratory Syncytial Virus (2015) (40)
- The Zika virus envelope protein glycan loop regulates virion antigenicity. (2018) (40)
- Respiratory syncytial virus (RSV)-induced airway hyperresponsiveness in allergically sensitized mice is inhibited by live RSV and exacerbated by formalin-inactivated RSV. (2000) (40)
- Vaccination with Human Papillomavirus Pseudovirus-Encapsidated Plasmids Targeted to Skin Using Microneedles (2015) (40)
- Comparative Serological Study for the Prevalence of Anti-MERS Coronavirus Antibodies in High- and Low-Risk Groups in Qatar (2019) (40)
- mRNA-1273 Protects against SARS-CoV-2 Beta Infection in Nonhuman Primates (2021) (40)
- Serum immunoglobulin G antibody subclass responses to respiratory syncytial virus F and G glycoproteins after primary infection (1986) (39)
- Atomic structures of enterovirus D68 in complex with two monoclonal antibodies define distinct mechanisms of viral neutralization (2018) (39)
- HIV-1 Vaccine-Induced T-Cell Reponses Cluster in Epitope Hotspots that Differ from Those Induced in Natural Infection with HIV-1 (2013) (39)
- Stabilized coronavirus spike stem elicits a broadly protective antibody (2021) (39)
- Replication-Defective Adenovirus Vectors with Multiple Deletions Do Not Induce Measurable Vector-Specific T Cells in Human Trials (2009) (38)
- Identification of an H-2D(b)-restricted CD8+ cytotoxic T lymphocyte epitope in the matrix protein of respiratory syncytial virus. (2005) (38)
- A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone (2020) (38)
- Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus (2017) (38)
- Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160. (2004) (37)
- Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network. (1994) (37)
- A flow cytometry-based assay to assess RSV-specific neutralizing antibody is reproducible, efficient and accurate. (2010) (37)
- Binding of Human Immunodeficiency Virus Type I to the C3b/C4b Receptor CRt (CD35) and Red Blood Cells in the Presence of Envelope-Specific Antibodies and Complement (1994) (37)
- Relative dominance of epitope-specific CD8+ T cell responses in an F1 hybrid mouse model of respiratory syncytial virus infection. (2007) (37)
- COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge (2021) (36)
- Protective Role of TNF-α in Respiratory Syncytial Virus Infection In Vitro and In Vivo (1996) (36)
- Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants (2021) (35)
- Genetic vaccine for respiratory syncytial virus provides protection without disease potentiation. (2014) (35)
- Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates (2021) (35)
- Viruslike Particles Encapsidating Respiratory Syncytial Virus M and M2 Proteins Induce Robust T Cell Responses. (2016) (35)
- A broadly neutralizing antibody protects against SARS-CoV, pre-emergent bat CoVs, and SARS-CoV-2 variants in mice (2021) (34)
- Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network. (1993) (34)
- HIV Monoclonal Antibodies: A New Opportunity to Further Reduce Mother-to-Child HIV Transmission (2014) (34)
- Pertussis toxin sensitization alters the pathogenesis of subsequent respiratory syncytial virus infection. (2000) (33)
- Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman Primates (2021) (32)
- DNA vaccines: A safe and efficient platform technology for responding to emerging infectious diseases (2009) (32)
- Antibody to the gp120 V1/V2 Loops and CD4+ and CD8+ T Cell Responses in Protection from SIVmac251 Vaginal Acquisition and Persistent Viremia (2014) (32)
- Targeting the Vaginal Mucosa with Human Papillomavirus Pseudovirion Vaccines Delivering Simian Immunodeficiency Virus DNA (2012) (31)
- Viruses, dendritic cells and the lung (2001) (31)
- Mucosal Delivery of Human Papillomavirus Pseudovirus-Encapsidated Plasmids Improves Potency of DNA Vaccination (2010) (31)
- Protective Efficacy of Nucleic Acid Vaccines Against Transmission of Zika Virus During Pregnancy in Mice. (2019) (31)
- Treatment with Anti-LFA-1 Delays the CD8+ Cytotoxic-T-Lymphocyte Response and Viral Clearance in Mice with Primary Respiratory Syncytial Virus Infection (2004) (30)
- Modified Vaccinia Virus Ankara Immunization Protects against Lethal Challenge with Recombinant Vaccinia Virus Expressing Murine Interleukin-4 (2004) (30)
- T Cell Receptor Clonotype Influences Epitope Hierarchy in the CD8+ T Cell Response to Respiratory Syncytial Virus Infection* (2010) (30)
- Glycan repositioning of influenza hemagglutinin stem facilitates the elicitation of protective cross-group antibody responses (2020) (30)
- HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial. (2014) (30)
- Development of a potent Zika virus vaccine using self-amplifying messenger RNA (2020) (30)
- Endocarditis and Infections of Intravascular Devices Due to Eikenella corrodens (1986) (29)
- Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial (2022) (29)
- Acute pubic osteomyelitis in athletes. (1992) (29)
- Construction and characterization of recombinant vaccinia viruses co-expressing a respiratory syncytial virus protein and a cytokine. (2001) (29)
- Immunization Against Viral Diseases (2009) (29)
- A comprehensive influenza reporter virus panel for high-throughput deep profiling of neutralizing antibodies (2020) (29)
- Evidence of Prior Exposure to Human Bocavirus as Determined by a Retrospective Serological Study of 404 Serum Samples from Adults in the United States (2009) (29)
- Memory Inflation Drives Tissue-Resident Memory CD8+ T Cell Maintenance in the Lung After Intranasal Vaccination With Murine Cytomegalovirus (2018) (29)
- Immunological goals for respiratory syncytial virus vaccine development. (2019) (29)
- Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Immunogenetic Considerations Underlying B-Cell Biology in the Development of a Pan-Subtype Influenza A Vaccine Targeting the Hemagglutinin Stem. (2018) (29)
- Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants (2021) (29)
- Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector (2016) (28)
- Zika Virus Vaccine Development. (2017) (28)
- Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial (2018) (28)
- Human Immunodeficiency Virus (HIV) Vaccine Trials: a Novel Assay for Differential Diagnosis of HIV Infections in the Face of Vaccine-Generated Antibodies (2006) (28)
- Whither monkeypox vaccination. (2011) (27)
- Respiratory Syncytial Virus (RSV) Neutralizing Antibodies at Birth Predict Protection from RSV Illness in Infants in the First 3 Months of Life (2020) (27)
- Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape. (2022) (27)
- Passive IgA monoclonal antibody is no more effective than IgG at protecting mice from mucosal challenge with respiratory syncytial virus. (1999) (27)
- Novel Approach for Differential Diagnosis of HIV Infections in the Face of Vaccine-Generated Antibodies: Utility for Detection of Diverse HIV-1 Subtypes (2006) (27)
- Characterization of Respiratory Syncytial Virus M- and M2-Specific CD4 T Cells in a Murine Model (2009) (26)
- Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya Virus. (2016) (26)
- Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate (2017) (26)
- Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans. (2007) (26)
- Elicitation of broadly protective immunity to influenza by multivalent hemagglutinin nanoparticle vaccines (2020) (25)
- Chimpanzee Adenovirus Vector Ebola Vaccine--Preliminary Report. (2015) (25)
- Broad sarbecovirus neutralizing antibodies define a key site of vulnerability on the SARS-CoV-2 spike protein (2020) (25)
- The complex relationship between respiratory syncytial virus and allergy in lung disease. (2003) (25)
- Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials (2015) (25)
- Epitope-Specific Regulatory CD4 T Cells Reduce Virus-Induced Illness while Preserving CD8 T-Cell Effector Function at the Site of Infection (2010) (25)
- DNA vaccination before conception protects Zika virus–exposed pregnant macaques against prolonged viremia and improves fetal outcomes (2019) (25)
- Prototype pathogen approach for pandemic preparedness: world on fire. (2020) (25)
- Boosting subdominant neutralizing antibody responses with a computationally designed epitope-focused immunogen (2018) (25)
- Pulmonary eosinophilia requires interleukin‐5, eotaxin‐1, and CD4+ T cells in mice immunized with respiratory syncytial virus G glycoprotein (2008) (25)
- Respiratory syncytial virus and other pneumoviruses: a review of the international symposium--RSV 2003. (2004) (25)
- Use of Hemagglutinin Stem Probes Demonstrate Prevalence of Broadly Reactive Group 1 Influenza Antibodies in Human Sera (2018) (24)
- Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjects. (2011) (24)
- Neutralizing antibody responses in Africa green monkeys naturally infected with simian immunodeficiency virus (SIVagm) (1999) (24)
- Structure-Based Design of Head-Only Fusion Glycoprotein Immunogens for Respiratory Syncytial Virus (2016) (24)
- Topical immunoprophylaxis of respiratory syncytial virus (RSV)-challenged mice with RSV-specific immune globulin. (1995) (24)
- Neonatal mice possess two phenotypically and functionally distinct lung-migratory CD103+ dendritic cell populations following respiratory infection (2017) (24)
- Epitope-Specific Serological Assays for RSV: Conformation Matters (2019) (23)
- Determinants and kinetics of cytokine expression patterns in lungs of vaccinated mice challenged with respiratory syncytial virus. (1997) (23)
- Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083. (2016) (23)
- Phase 1 Study of Pandemic H1 DNA Vaccine in Healthy Adults (2015) (23)
- Iterative structure-based improvement of a respiratory syncytial virus fusion glycoprotein vaccine (2016) (23)
- IL-13 is associated with reduced illness and replication in primary respiratory syncytial virus infection in the mouse (2006) (23)
- Perinatal transmission of human immunodeficiency virus‐1 infection and maternal immunization strategies for prevention (1992) (23)
- Protecting the family to protect the child: vaccination strategy guided by RSV transmission dynamics. (2014) (22)
- Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses. (2021) (22)
- DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial (2018) (22)
- Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater In Vivo Protection than the Murine Precursor of Palivizumab (2017) (22)
- A Prime-Pull-Amplify Vaccination Strategy To Maximize Induction of Circulating and Genital-Resident Intraepithelial CD8+ Memory T Cells (2019) (22)
- Structure-Based Design of Nipah Virus Vaccines: A Generalizable Approach to Paramyxovirus Immunogen Development (2020) (22)
- Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes (2020) (21)
- Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants. (2020) (21)
- Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice (2021) (21)
- Importance of neutralizing monoclonal antibodies targeting multiple antigenic sites on MERS-CoV Spike to avoid neutralization escape. (2018) (21)
- Allergen-Induced Airway Hyperresponsiveness Mediated by Cyclooxygenase Inhibition Is Not Dependent on 5-Lipoxygenase or IL-5, but Is IL-13 Dependent1 (2005) (21)
- Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality (2020) (21)
- Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. (1996) (21)
- The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network. (1991) (21)
- HIV‐1 recombinant gp160 vaccine given in accelerated dose schedules (1994) (20)
- Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals. (2015) (20)
- Cytokine release and innate immunity in respiratory viral infection (1996) (20)
- Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group. (1996) (20)
- An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial (2017) (20)
- Vaccination with pertussis toxin alters the antibody response to simultaneous respiratory syncytial virus challenge. (1999) (20)
- Phase I Randomized Clinical Trial of VRC DNA and rAd5 HIV-1 Vaccine Delivery by Intramuscular (IM), Subcutaneous (SC) and Intradermal (ID) Administration (VRC 011) (2014) (20)
- Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses (2021) (20)
- Allergen-induced airway hyperresponsiveness mediated by cyclooxygenase inhibition is not dependent on 5-lipoxygenase or IL-5, but is IL-13 dependent. (2006) (20)
- A Numerically Subdominant CD8 T Cell Response to Matrix Protein of Respiratory Syncytial Virus Controls Infection with Limited Immunopathology (2016) (20)
- Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial. (2021) (20)
- Pulmonary Dendritic Cell Subsets Shape the Respiratory Syncytial Virus–Specific CD8+ T Cell Immunodominance Hierarchy in Neonates (2017) (19)
- RhoA-Derived Peptide Dimers Share Mechanistic Properties with Other Polyanionic Inhibitors of Respiratory Syncytial Virus (RSV), Including Disruption of Viral Attachment and Dependence on RSV G (2004) (19)
- Infection with HIV-1 (1998) (19)
- SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques (2021) (19)
- GM-CSF Production Allows the Identification of Immunoprevalent Antigens Recognized by Human CD4+ T Cells Following Smallpox Vaccination (2011) (19)
- A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group. (2000) (18)
- DNA Priming for Seasonal Influenza Vaccine: A Phase 1b Double-Blind Randomized Clinical Trial (2015) (18)
- HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces gp41 Antibody Immunodominance in Rhesus Macaques (2017) (17)
- Crystal Structure and Immunogenicity of the DS-Cav1-Stabilized Fusion Glycoprotein From Respiratory Syncytial Virus Subtype B (2019) (17)
- Vaccine-specific antibody responses induced by HIV-1 envelope subunit vaccines. (1997) (16)
- Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial (2019) (16)
- Clonotype‐specific avidity influences the dynamics and hierarchy of virus‐specific regulatory and effector CD4+ T‐cell responses (2014) (16)
- Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160 (1992) (16)
- Vaccine Development in the Twenty‐First Century: Changing Paradigms for Elusive Viruses (2009) (16)
- Serological responses to candidate AIDS vaccines. (1994) (15)
- Progress with PfSPZ Vaccine, a radiation attenuated Plasmodium falciparum sporozoite vaccine (2014) (15)
- Inhibition of respiratory syncytial virus by RhoA-derived peptides: implications for the development of improved antiviral agents targeting heparin-binding viruses. (2004) (15)
- Next-Generation Influenza Vaccines. (2020) (15)
- Phase I/II preventive vaccine trials : conference summary (1995) (15)
- Binding of human immunodeficiency virus type 1 to the C3b/C4b receptor CR1 (CD35) and red blood cells in the presence of envelope-specific antibodies and complement. National Institutes of Health AIDS Vaccine Clinical Trials Networks. (1994) (15)
- Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidates (2020) (15)
- Antiviral Activity of RhoA-Derived Peptides against Respiratory Syncytial Virus Is Dependent on Formation of Peptide Dimers (2003) (15)
- Chikungunya in the Americas: Recommendations and Conclusions. (2016) (15)
- Vaccination by microneedle patch with inactivated respiratory syncytial virus and monophosphoryl lipid A enhances the protective efficacy and diminishes inflammatory disease after challenge (2018) (15)
- Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F (2017) (14)
- Subtypes of type I IFN differentially enhance cytokine expression by suboptimally stimulated CD4+ T cells (2013) (14)
- Comparison of adjuvants to optimize influenza neutralizing antibody responses. (2019) (14)
- Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01LS in HIV-1-Exposed Newborn Infants. (2021) (14)
- Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group. (1998) (13)
- Increased detection of herpesvirus DNA in idiopathic pulmonary fibrosis. (2001) (13)
- OMIP‐061: 20‐Color Flow Cytometry Panel for High‐Dimensional Characterization of Murine Antigen‐Presenting Cells (2019) (13)
- Antibody-Induced Internalization of the Human Respiratory Syncytial Virus Fusion Protein (2017) (13)
- Prophylaxis with respiratory syncytial virus F-specific humanized monoclonal antibody delays and moderately suppresses the native antibody response but does not impair immunity to late rechallenge. (1999) (13)
- Safety and pharmacokinetics of vitamin A therapy for infants with respiratory syncytial virus infections (1995) (13)
- The immune space: a concept and template for rationalizing vaccine development. (2014) (12)
- Development and Standardization of a High-Throughput Multiplex Immunoassay for the Simultaneous Quantification of Specific Antibodies to Five Respiratory Syncytial Virus Proteins (2019) (12)
- Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost. (2015) (12)
- Influenza infected newborn and adult monkeys exhibit a strong primary antibody response to hemagglutinin stem. (2020) (12)
- Attenuated activation of pulmonary immune cells in mRNA-1273 vaccinated hamsters after SARS-CoV-2 infection. (2021) (12)
- Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012) (2016) (12)
- Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial (2022) (12)
- SARS-CoV-2 Vaccines Elicit Durable Immune Responses in Infant Rhesus Macaques (2021) (11)
- Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus (2020) (11)
- P15-17. Social media as a tool for engaging and educating audiences around HIV vaccine research and clinical trial participation (2009) (11)
- Evaluation of mRNA-1273 against SARS-CoV-2 B.1.351 Infection in Nonhuman Primates (2021) (11)
- Antigenic competition in CD4+ T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial (2019) (11)
- Preparing for the Next Influenza Pandemic: The Development of a Universal Influenza Vaccine (2019) (11)
- Proposal for Human Respiratory Syncytial Virus Nomenclature below the Species Level (2021) (11)
- New Approaches to Vaccine Adjuvants: Inhibiting the Inhibitor (2006) (10)
- Vaccines Against Human Hookworm Disease (2004) (10)
- Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in nonhuman primates is coincident with an anamnestic antibody response in the lower airway (2021) (10)
- LY-CoV1404 potently neutralizes SARS-CoV-2 variants (2021) (10)
- A high-throughput inhibition assay to study MERS-CoV antibody interactions using image cytometry (2018) (10)
- Human amniotic fluid antibodies protect the neonate against respiratory syncytial virus infection. (2016) (9)
- Protection against SARS-CoV-2 Beta Variant in mRNA-1273 Boosted Nonhuman Primates (2021) (9)
- Therapeutic Neutralizing Monoclonal Antibodies: Report of a Summit sponsored by Operation Warp Speed and the National Institutes of Health (2020) (9)
- Faculty Opinions recommendation of Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. (2009) (9)
- A unique nanoparticulate TLR9 agonist enables a HA split vaccine to confer Fc&ggr;R-mediated protection against heterologous lethal influenza virus infection (2018) (9)
- mRNA-1273 efficacy in a severe COVID-19 model: attenuated activation of pulmonary immune cells after challenge (2021) (8)
- Recent progress in immune‐based interventions to prevent HIV‐1 transmission to children (2017) (8)
- Chimeric Fusion (F) and Attachment (G) Glycoprotein Antigen Delivery by mRNA as a Candidate Nipah Vaccine (2021) (8)
- WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants – Key considerations for global use (2022) (8)
- A unique combination adjuvant modulates immune responses preventing vaccine-enhanced pulmonary histopathology after a single dose vaccination with fusion protein and challenge with respiratory syncytial virus. (2019) (8)
- CD8+ TCR Transgenic Strains Expressing Public versus Private TCR Targeting the Respiratory Syncytial Virus KdM282–90 Epitope Demonstrate Similar Functional Profiles (2014) (8)
- Prefusion coronavirus spike proteins and their use (2017) (8)
- A SARS-CoV-2 mRNA Vaccine - Preliminary Report. Reply. (2020) (8)
- Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network. (1993) (8)
- Homologous Boosting with Adenoviral Serotype 5 HIV Vaccine (rAd5) Vector Can Boost Antibody Responses despite Preexisting Vector-Specific Immunity in a Randomized Phase I Clinical Trial (2014) (7)
- Safety profile of HIV vaccination: first 1000 volunteers of AIDS vaccine evaluation group. NIAID AIDS Vaccine Clinical Trials Network. (1994) (7)
- Cross-reactive coronavirus antibodies with diverse epitope specificities and extra-neutralization functions (2020) (7)
- Demonstration of elevated levels of active cathepsin S in dextran sulfate sodium colitis using a new activatable probe (2015) (6)
- Functional Profiling of Antibody Immune Repertoires in Convalescent Zika Virus Disease Patients (2021) (6)
- Structure-based design of stabilized recombinant influenza neuraminidase tetramers (2021) (6)
- Prefusion 2019-nCoV spike glycoprotein with a single receptor-binding domain up (2020) (6)
- An R848 conjugated influenza virus vaccine elicits robust IgG to hemagglutinin stem in a newborn nonhuman primate model. (2020) (6)
- Model Informed Development of VRC01 in Newborn Infants Using a Population Pharmacokinetics Approach (2020) (5)
- Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events (2012) (5)
- A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination (2022) (5)
- Crystal structure of Middle-East Respiratory Syndrome (MERS) coronavirus neutralizing antibody JC57-14 isolated from a vaccinated rhesus macaque. (2018) (5)
- Correction: Corrigendum: Protection against malaria at 1 year and immune correlates following PfSPZ vaccination (2016) (5)
- Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza viruses (2022) (5)
- Hospitalization costs of respiratory syncytial virus infection. (2001) (5)
- Meeting the Challenge of Vaccine Design To Control HIV and Other Difficult Viruses (2011) (5)
- Level of Maternal Respiratory Syncytial Virus (RSV) F Antibodies in Hospitalized Children and Correlates of Protection. (2021) (5)
- Detection of Bacteremia and Fungemia: Microscopic Examination of Peripheral Blood Smears (1984) (5)
- Author Correction: Next-generation influenza vaccines: opportunities and challenges (2020) (4)
- Antifusion activity in sera from persons infected with human immunodeficiency virus type 1 (1990) (4)
- Phenotype and Hierarchy of Two Transgenic T Cell Lines Targeting the Respiratory Syncytial Virus KdM282-90 Epitope Is Transfer Dose-Dependent (2016) (4)
- Growth of human cell lines in BALB/c mice. (1990) (4)
- Severe Acute Respiratory Syndrome Coronavirus 2 Prevalence, Seroprevalence, and Exposure among Evacuees from Wuhan, China, 2020 (2020) (4)
- Author Correction: Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses (2019) (4)
- Trypsin treatment unlocks barrier for zoonotic coronaviruses infection (2019) (4)
- VRC 004: Safety and Immunogenicity of a Multiclade HIV-1 DNA Vaccine in Healthy Uninfected Adults (VRC-HIVDNA009-00-VP) (2005) (4)
- An optimized messenger RNA vaccine candidate protects non-human primates from Zika virus infection (2022) (3)
- V 3-Specific Neutralizing Antibodies in Sera From HIV-1 gp 160-immunized Volunteers Block Virus Fusion and Act Synergistically with Human Monoclonal Antibody to the Conformation-dependent CD 4 Binding Site of gp 120 (2013) (3)
- Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. (2020) (3)
- CD4 T cell epitope abundance in ferritin core potentiates responses to hemagglutinin nanoparticle vaccines (2022) (3)
- A prefusion-stabilized RSV F subunit vaccine elicits B cell responses with greater breadth and potency than a postfusion F vaccine (2022) (3)
- Prototype Pathogen Approach for Vaccine and Monoclonal Antibody Development: A Critical Component of the NIAID Plan for Pandemic Preparedness (2022) (3)
- Elicitation of pneumovirus-specific B cell responses by a prefusion-stabilized respiratory syncytial virus F subunit vaccine (2022) (3)
- Vitamin A therapy for respiratory syncytial virus infection. (1997) (3)
- Human respiratory syncytial virus reduces the number of cells in S-phase and increases GADD153 expression in HEp-2 cells. (2009) (3)
- Limited flavivirus cross-reactive antibody responses elicited by a ZIKV DNA vaccine candidate in humans. (2021) (3)
- rAd5 prime/NYVAC-B boost regimen is superior to NYVAC-B prime/rAd5 boost regimen for both response rates and magnitude of CD4 and CD8 T-cell responses (2012) (2)
- CAF08 adjuvant enables single dose protection against respiratory syncytial virus infection in murine newborns (2022) (2)
- S01-04 OA. Phenotypic analyses of CD8+ T cells that mediate virus inhibition from HIV-1 vaccinees and HIV-1+ virus controllers (2009) (2)
- HIV-DNA Priming Alters T Cell Responses (2011) (2)
- DNA and recombinant adenovirus serotype 35 and 5 preventive HIV-1 vaccines with Env A inserts elicit cross-clade binding and V1V2 antibodies (2012) (2)
- Recurrent Respiratory Syncytial Virus Infection in a CD14-Deficient Patient (2022) (2)
- Development of an AIDS vaccine. Biological and ethical challenges. (1990) (2)
- Reply to Rottinghaus and Poland (2008) (2)
- Co-immunization with hemagglutinin stem immunogens elicits cross-group neutralizing antibodies and broad protection against influenza A viruses. (2022) (2)
- rAd5/NYVAC-B is superior to NYVAC-B/rAd5 and is dependent on rAd5 dose for neutralizing antibody responses against HIV-1 (2012) (1)
- Human antibody immune responses are personalized by selective removal of MHC-II peptide epitopes (2021) (1)
- Iconographies supplémentaires de l'article : Respiratory syncytial virus infection in the absence of STAT1 results in airway dysfunction, airway mucus, and augmented IL-17 levels (2011) (1)
- Multiple antibody specificities (gp41, V1V2, and V3) elicited in the phase II multiclade (A, B, C) HIV-1 DNA prime, rAd5 boost vaccine trial (2012) (1)
- Design of nanoparticulate group 2 influenza hemagglutinin stem antigens that activate unmutated ancestor B cell receptors of broadly neutralizing antibody lineages (2018) (1)
- 2904. Protective Efficacy of Nucleic Acid Vaccines Against Transmission of Zika Virus During Pregnancy in Mice (2019) (1)
- Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge one year later (2022) (1)
- Multiple antibody specificities (gp41, V1V2, and V3) elicited in the phase II multiclade (A, B, C) HIV-1 DNA prime, rAd5 boost vaccine trial (2012) (1)
- An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults (2023) (1)
- Interface between Animal Models and Clinical Phase I Trials Workshop: Conference Summary (1995) (1)
- P14-10. Comparable immunogenicity of VRC DNA and rAd5 HIV-1 vaccines delivered by intramuscular, subcutaneous and intradermal routes in healthy adults (VRC 011) (2009) (1)
- Functional reconstitution of the MERS CoV receptor binding motif (2022) (1)
- Vaccines for Emerging Viral Diseases (2016) (1)
- Author Correction: Next-generation influenza vaccines: opportunities and challenges (2020) (1)
- P18-06. Increased HIV-specific immunity in HIV-infected individuals vaccinated with a DNA prime, rAd5 boost regimen (2009) (1)
- Age-related expression of naive (CD45RA/62L) and activation (HLA DR/CD38) surface markers on CD4(+) and CD8(+) T-cell in normal children (birth to 18 years) (2002) (1)
- Prolonged Production of TNF- (2004) (1)
- Divergent age-related humoral correlates of protection against respiratory syncytial virus infection in older and young adults: a pilot, controlled, human infection challenge model. (2022) (1)
- Structure of the RSV F protein in the post-fusion conformation (2011) (1)
- Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial (2022) (1)
- Safety, Tolerability, Pharmacokinetics, and Immunogenicity of mAb114: A Phase 1 Trial of a Therapeutic Monoclonal Antibody Targeting Ebola Virus Glycoprotein (2019) (1)
- Receptor binding and proteolysis do not induce large conformational changes in the SARS-CoV spike (2018) (1)
- Vaccination Against Respiratory Syncytial Virus (2020) (1)
- Clinical trials of AIDS vaccines in seronegative volunteers: vectors and combinations. (1992) (1)
- An influenza H1 hemagglutinin stem-only immunogen elicits a broadly cross-reactive B cell response in humans (2023) (1)
- Crystal Structure of RSV-Neutralizing Human Antibody D25 (2013) (0)
- NK T Cells Contribute to Expansion of CD8 (cid:1) T Cells and Amplification of Antiviral Immune Responses to Respiratory Syncytial Virus (2002) (0)
- Persistent Viremia Vaginal Acquisition andmac 251 from SIV T Cell Responses in Protection + and CD 8 + Antibody to the gp 120 V 1 / V 2 Loops and CD 4 Genoveffa (2014) (0)
- Crystal structure of Middle-East Respiratory Syndrome (MERS) coronavirus neutralizing antibody JC57-14 isolated from a vaccinated rhesus macaque in complex with MERS Receptor Binding Domain (2018) (0)
- Crystal Structure of 101F Fab Bound to 15-mer Peptide Epitope (2010) (0)
- What does the report of the USMHRP Phase III study in Thailand mean for HIV and for vaccine developers? (2009) (0)
- Potential for Directing Appropriate Responses to Vaccines by Cytokine Manipulation (1996) (0)
- Future opportunities for passive immunity against viral diseases. (2011) (0)
- TLR agonists induce sustained IgG to hemagglutinin stem and modulate T cells following newborn vaccination (2022) (0)
- Next-generation influenza vaccines: opportunities and challenges (2020) (0)
- Epitope-Specific Regulatory T cells Differentially Modulate the CD8 T Cell Response to Respiratory Syncytial Virus in Mice (45.29) (2009) (0)
- Author Correction: Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses (2019) (0)
- Structure of MERS-Coronavirus Spike Receptor-binding Domain (England1 Strain) in Complex with Vaccine-Elicited Murine Neutralizing Antibody D12 (Crystal Form 1) (2015) (0)
- 93. Novel recombinant measles virus vaccine prevents measles virus disease in rhesus macaques (2022) (0)
- McLellan Respiratory Syncytial Virus Structure-Based Design of a Fusion Glycoprotein Vaccine for (2014) (0)
- SARS-CoV-2 vaccines induce potent immune responses in infant rhesus macaques (2021) (0)
- Authors' Addendum (1991) (0)
- A single-dose live-attenuated vaccine prevents Zika virus pregnancy transmission and testis damage (2017) (0)
- Reply to: Vitamin A for varicella (1994) (0)
- Augmentation of allergic inflammation by cyclooxygenase (COX) inhibition does not depend on STAT6 signaling (2003) (0)
- Update on policy change proposal to end Institutional Biosafety Committee (IBC) review of rDNA vaccine clinical trials (2012) (0)
- Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein (2017) (0)
- Crystal Structure of Motavizumab Fab Bound to Peptide Epitope (2010) (0)
- A Multivalent Polyomavirus Vaccine Elicits Durable Neutralizing Antibody Responses in Macaques (2022) (0)
- Animal models for COVID-19 (2020) (0)
- A single immunization with CAF08 provides newborns with Th1-mediated protection against Respiratory Syncytial Virus infection (2021) (0)
- SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness (2020) (0)
- Publisher Correction: Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis (2018) (0)
- Tackle the Spectrum Of Persistent and Emerging HIV Challenges Seeking a Less Pereect Host Salvage Therapy (2016) (0)
- Tribute to David T. Karzon, MD and Robert M. Chanock, MD (2011) (0)
- Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic (2017) (0)
- ZIKV-specific CD8 T cell immunity in humans is affected by DENV pre-exposure (2018) (0)
- After Respiratory Syncytial Virus Challenge Virus G Glycoprotein-Induced Eosinophilia IL-13 Is Sufficient for Respiratory Syncytial (2003) (0)
- Nanoparticle display of prefusion coronavirus spike elicits S1-focused cross-reactive protection across divergent subgroups (2022) (0)
- Review Viruses, dendritic cells and the lung (2001) (0)
- Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis (2018) (0)
- An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial (2017) (0)
- IDENTIFICATION OF HUMAN T CELL EPITOPES IN THE EBOLAVIRUS GLYCOPROTEIN FOLLOWING VACCINATION WITH CHAD3 EBO Z GP AND MVA BN (2017) (0)
- Vaccine-elicitation of cross-group neutralizing protective antibodies to influenza A viruses (2022) (0)
- 487. Analysis of the Association between Specific Antibody Response against Respiratory Syncytial Virus Fusion Protein Conformations and Life-Threatening Infection in Previously Healthy Infants (2022) (0)
- , In Vivo Infection Improves Protection against Lentiviral In Vitro Neutralizing HIV-1 Antibody Enhanced Potency of a Broadly (2014) (0)
- Safety and immunogenicity of the heterologous prime-boost ebolavirus vaccine regimen CHAD3-EBO Z and MVA-BN (R) FILO in healthy UK adults (2015) (0)
- Dependent on 5-Lipoxygenase or IL-5 , but Is IL-13 Cyclooxygenase Inhibition Is Not Dependent Hyperresponsiveness Mediated by Allergen-Induced Airway (2005) (0)
- Sequence-Signature Optimization Enables Improved Identification of Human HV6-1-Derived Class Antibodies That Neutralize Diverse Influenza A Viruses (2021) (0)
- Running Title: Serological Study of Human Bocavirus (2009) (0)
- against Monkeypox Subunit Recombinant Vaccine Protects (2006) (0)
- Safety and Immunogenicity of DNAVaccines Encoding Ebolavirus and Marburgvirus Wild- Type Glycoproteins in a Phase I Clinical Trial (2015) (0)
- Augmentation of allergic inflammation by cyclooxygenase inhibition is not dependent on IL-4 (2002) (0)
- Progress in vaccine development for infectious diseases-a Keystone Symposia report. (2023) (0)
- Atomic structures of enterovirus D68 in complex with two monoclonal antibodies define distinct mechanisms of viral neutralization (2018) (0)
- Differential Specificity and Immunogenicity of Adenovirus Type 5 Neutralizing Antibodies Elicited by Natural Infection or Immunization (cid:1) (2009) (0)
- Crystal structure of vaccine-elicited pan- influenza H1N1 neutralizing murine antibody 441D6. (2018) (0)
- Structure of unbound MERS-CoV spike receptor-binding domain (England1 strain). (2015) (0)
- Crystal Structure of Prefusion-stabilized RSV F Variant DS-Cav1-TriC at pH 9.5 (2013) (0)
- 1354Toll-like Receptor Agonists Alter the CD8+ T Cell Response Hierarchy in Neonates During Respiratory Syncytial Virus Infection (2014) (0)
- ACUTE PUBIC OSTEOMYELITIS. AUTHORS' REPLY (1993) (0)
- DNADelivering Simian Immunodeficiency Virus Papillomavirus Pseudovirion Vaccines Targeting the Vaginal Mucosa with Human (2011) (0)
- Neutralizing Activ ity of Zika Virus-Immune Sera Identifies a Single Viral Serotype Graphical (0)
- The Journey to RSV Vaccines - Heralding an Era of Structure-Based Design. (2023) (0)
- Systemic PGE2 neutralization results in enhanced allergic pulmonary inflammation in a murine model (2004) (0)
- Early prophylaxis impact for newborns at risk for HIV-1 transmission at birth: viral clearance and attenuation with neutralizing monoclonal antibodies in infant rhesus macaques (2016) (0)
- Title: Immune Correlates of Protection by mRNA-1273 Immunization against 1 SARS-CoV-2 Infection in Nonhuman Primates (2021) (0)
- Immunoglobulin Class Switching During RSV Infection Is PKR-Dependent (38.1) (2010) (0)
- Crystal Structure and Immunogenicity of the DS-Cav1-Stabilized Fusion Glycoprotein From Respiratory Syncytial Virus Subtype B. (2019) (0)
- Comprar Challenges And Opportunities For Respiratory Syncytial Virus Vaccines (Current Topics In Microbiology And Immunology, Vol. 372) | Anderson, L. | 9783642389184 | Springer (2013) (0)
- Faculty Opinions recommendation of Lung CD103+ dendritic cells efficiently transport influenza virus to the lymph node and load viral antigen onto MHC class I for presentation to CD8 T cells. (2012) (0)
- 867 RSV infection decreases type 2 cytokine concentrations during allergen sensitization, yet increases airway hyperresponsiveness in mice (2000) (0)
- On the Trail of an Effective HIV Vaccine (2004) (0)
- RSV infection in absence of STAT1 results in airway dysfunction, airway mucus, and augmented IL-17 and IL-23 expression (2005) (0)
- The Current State of RSV Vaccine Development (2014) (0)
- Safety and immunogenicity of the VRC recombinant multiclade HIV-1 adenoviral vector vaccine alone or in combination with the VRC multiclade HIV-1 DNA plasmid vaccine in healthy African adults (2009). (2007) (0)
- Crystal Structure of 101F Fab Bound to 17-mer Peptide Epitope (2010) (0)
- Clinical Trials of DNA and Recombinant Adenovector (rAd) Vaccines for HIV (2005) (0)
- VRC 311: Phase I Clinical Trial of a Virus-Like Particle Chikungunya Vaccine in Healthy Adults (2013) (0)
- Faculty Opinions recommendation of Antiviral CD8+ T cell effector activities in situ are regulated by target cell type. (2011) (0)
- Molecular Dissection Of Human Antibody Responses Following Prefusion-Stabilized RSV F Vaccination (2020) (0)
- Structural basis for antibody recognition of vulnerable epitopes on Nipah virus F protein (2022) (0)
- Recombinant gp 120 Subunit Vaccines Virus Type 1 while Participating in Trials of Persons Infected by Human Immunodeficiency Immunological and Virological Analyses of (1998) (0)
- Structure-based vaccines for respiratory viruses (2018) (0)
- Glycan repositioning of influenza hemagglutinin stem facilitates the elicitation of protective cross-group antibody responses (2020) (0)
- SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness Preview (2020) (0)
- TLR agonists induce sustained IgG to hemagglutinin stem and modulate T cells following newborn vaccination (2022) (0)
- Infectious bronchitis vaccines--a comment. (1988) (0)
- Challenges and Prospects for the Development of an HIV Vaccine (2009) (0)
- A Model Interaction for Structural Biology and Health Research: Implications of the Antibody D25 bound to the RSV Pre‐Fusion Glycoprotein (LB100) (2014) (0)
- Structure of MERS-Coronavirus Spike Receptor-binding Domain (England1 Strain) in Complex with Vaccine-Elicited Murine Neutralizing Antibody D12 (Crystal Form 2) (2015) (0)
- EpitopeImmunopathology Caused by a Dominant Cell Epitope Protect against T + Responses against a Subdominant CD8 (2010) (0)
- Crystal Structure of Respiratory Syncytial Virus Fusion Glycoprotein Stabilized in the Prefusion Conformation by Human Antibody D25 (2013) (0)
- A 17-year-old with rash, fever, myalgias, and nephritis. (1998) (0)
- Virus-specific Tregs are terminally differentiated upon peripheral activation and dependent on thymic output after both primary and secondary infection (P1035) (2013) (0)
- Use of Hemagglutinin Stem Probes Demonstrate Prevalence of Broadly Reactive Group 1 Influenza Antibodies in Human Sera (2018) (0)
- Rapid development of a DNAvaccine for Zika virus (2016) (0)
- Post-exposure treatment with neutralizing monoclonal antibodies prevents SHIV infection in infant rhesus macaques and limits establishment of latent viral reservoirs (VAC11P.1102) (2015) (0)
- , Roberto Pulmonary Fibrosis in Lungs of Patients with Idiopathic Herpesvirus DNA Is Consistently Detected (2003) (0)
- Update on policy change proposal to end Institutional Biosafety Committee (IBC) review of rDNA vaccine clinical trials (2012) (0)
- Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses (2019) (0)
- Early Innate and Adaptive Immune Responses to Investigational Human Immunodeficiency Virus (HIV)-1 Vaccines (VRC 016 study) (2015) (0)
- Selected talk 2 MCMV exploits the spleen as a transfer hub for systemic dissemination upon oronasal inoculation (2015) (0)
- rAd5 prime/NYVAC-B boost regimen is superior to NYVAC-B prime/rAd5 boost regimen for both response rates and magnitude of CD4 and CD8 T-cell responses (2012) (0)
- rAd5/NYVAC-B is superior to NYVAC-B/rAd5 and is dependent on rAd5 dose for neutralizing antibody responses against HIV-1 (2012) (0)
- P15-30 LB. An evaluation of prescreen recruitment data: enrolling racial/ethnic minorities in Phase I HIV vaccine clinical trials (2009) (0)
- DNA and recombinant adenovirus serotype 35 and 5 preventive HIV-1 vaccines with Env A inserts elicit cross-clade binding and V1V2 antibodies (2012) (0)
- P14-12. Safety and tolerability of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular, subcutaneous and intradermal administration in healthy adults (2009) (0)
- P19-57 LB. Gene-based vaccination protects against mucosal infection by a heterologous highly pathogenic SIV isolate in rhesus monkeys (2009) (0)
- Efficacy of pediatric SARS-CoV-2 vaccines against high-dose B.1.617.2 challenge one year after vaccination of infant rhesus macaques (2022) (0)
This paper list is powered by the following services:
Other Resources About Barney S. Graham
What Schools Are Affiliated With Barney S. Graham?
Barney S. Graham is affiliated with the following schools:
